Outcome of unrelated-donor allogeneic hematopoietic cell transplantation for 29 recipients with severe aplastic anemia
10.3760/cma.j.issn.0254-1785.2017.02.004
- VernacularTitle:无关供者造血干细胞移植治疗重型再生障碍性贫血29例的疗效分析
- Author:
Jian ZHOU
;
Yanli ZHANG
;
Yuewen FU
;
Quande LIN
;
Lijie LIANG
;
Fengkuan YU
;
Qian WANG
;
Lijlie HAN
;
Yingling ZU
;
Baijun FANG
;
Xudong WEI
;
Yongping SONG
- Keywords:
Severe aplastic anemia;
Hematopoietic stem cell transplantation;
Unrelated donor;
Matched sibling donor
- From:
Chinese Journal of Organ Transplantation
2017;38(2):78-83
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the effectiveness of unrelated donor (URD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of severe aplastic anemia (SAA),and the difference between URD allo-HSCT and matched sibling donor (MSD) allo-HSCT.Methods According to the source of donors,the SAA patients subject to allo-HSCT were divided into MSD allo-HSCT group (MSD group) and URD allo-HSCT group (URD group) from October 2001 to December 2016 in Henan Cancer Hospital.The efficacy and transplantation related complications were compared between two groups.Results There were no statistically significant differences in hematopoietic reconstitution and graft rejection between two groups.The incidence of grade Ⅱ-Ⅳ acute GVHD and chronic GVHD was higher in the URD group than in the MSD group (30.76％ vs.8.57％,P =0.026;26.92％ vs.5.71％,P =0.021).However,other transplant-related complications including pulmonary complications and hemorrhagic cystitis,incidence of EBV and CMV reactivation and venous occlusive disease showed no significant difference between two groups.The estimated 5-year over survival was (73.6 ± 8.7) ％ in the MSD group and (72.7 ± 9.5) ％ in the URD group (P =0.878).There was no significant difference in 5-year disease-free survival between two groups (73.6 ± 8.7％ vs.70.3 ± 10.2,P =0.668).Conclusion URD-HSCT is a novel treatment approach and could be considered as first-line therapy in selected patients without MSD.
